Iovance Biotherapeutics: The High-Risk Cancer Stock I Think Could Change a Portfolio by 2036 [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Penny stocks sometimes offer significant upside potential. However, they also carry far more risk than more established corporations. Before investing in a penny stock, investors must do their due diligence (as usual) and ensure they are comfortable with the heightened risk and volatility. Let's consider one penny stock that looks very risky but, given near-perfect execution, could see its shares skyrocket over the next decade: Iovance Biotherapeutics (NASDAQ: IOVA) . Here is more on this cancer-fighting company. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Iovance is finding some success Iovance Biotherapeutics developed Amtagvi, a medicine manufactured from patients' own cancer -fighting cells. Amtagvi earned approval for melanoma in early 2024. Although the stock has not
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) had its price target raised by UBS Group AG from $2.00 to $4.00. They now have a "neutral" rating on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) was upgraded by Citizens Jmp from "market perform" to "market outperform". They now have a $5.00 price target on the stock.MarketBeat
- Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success [Yahoo! Finance]Yahoo! Finance
- Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present at Upcoming ConferencesGlobeNewswire
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- IOVA's page on the SEC website